BTG's upbeat close period update (imo) further confirms the turnaround.
With recurring royalty revenues expected to be up by about 5% and R&D spend in line, and a product pipeline to die for, i believe they are cheap, and a real growth stock for the future.
Any comments.

Greekman, without reading the full story, it looks as though the AZ-news is giving BTG something like a big-smile.
Looking good to me, up 9%-ish on the News....
EDIT (18Aug09)- Down 4.5% uyesterday on cancer-drug news will trigger $7m milestone paymnet - Er, what? + Still, it's up a tad today. (Abt. 187 to buy.)
EDIT-(26Aug09). Director sharedealing - no wonder they call it thus...their option shares are sold "to cover tax liabilities" - well, frankly if this is how they treat free shares, it shows little confidence in the next 3-months ( ie seeing-out 2009).
Oh deary. I think they should hold onto them at least until the end of the Tax-year...eh?
EDIT (16Oct09)- 199 = 2+ soon, now that's progress.
EDIT (17Nov09)- 199 a few weeks ago, now 165 after some selling today a buyer appeared and bought what looks like 200k shares (c. 300k) in 3 tranches.

BTG Licenses ReGel to Allergan for use in diseases of the eye.

Under the terms of the agreement, BTG will receive an undisclosed upfront payment, and potential additional future milestones and royalties on product sales.

Good news (I think) but 'why the secrecy' of the amount they will receive.

Although I have seen this before to not state the deal value of an upfront payment is in my experience very rare.

So the RNS does not tell us much at all, presumably it is a good deal for BTG, but how can we tell.

Happy New Year
But - I must take a different view to yours Greekman - in that it is my experience that good commercially-focussed companies usually don't give details. They may talk of Milestone payments and Royalties, but so often the RNS is somewhat short on pennies (or Pounds,). I've always thought this was to prevent other parties from understanding their competitors....
- For example if BTG is selling a minor treatment, then they'll approach say three or more potential partners. Hopefully one will bite and make a bid - this may be less than the others, because BTG believes the Return is more-certain (and hopefully better overall). To avoid upsetting the others, the "deal" is somewhat fudged - after all they may want to get top-dollar with one of the disapointed parties. By showinig their hand (that BTG settled for less, say) they may miss out on a far more finacially important deal.....

Sadly many also-ran companies (few on the Main Mkt. IMHO) use the same technique to pump-up their deals, E.G. by trying to use the good-name of a larger-player as though this creates a "value" for their technology, when in fact all they have is an "understanding" - which is pretty worthless. These "snipets" are then used by Rampers to justify rapid price-rises based on nothiing more than Hope . . . and the eagerness of punters to be "in" at the start - whereas the truth is they are being drawn into a sp that is already overvalued by a factor of ten.
- I hold BTG, in case anyone thinks I'm grininig any axe.
Oh and I'm still happy, waiting for my reward.

Hi Hangon,

I for one don't think you are 'grinding any axe', but I stick to my comments re detail, although I do see your point re keeping the figures from potential competitors.
Like you waiting for the reward which I am confident will come.

Regards Greek.

Thanks for that on BTG - - - - BTW are you reading OXB's RNS (today)...?

I hold that also, and am impressed by the irregular updates. . . . looks good to me for the US patent-holders have invested in OXB - looking for an extra return on their efforts, I guess.


EDIT (Oct2010), UPDATE - FWIW, I've sold most of my BTG-holding at 229, as a result of IC article that paints a less-rosey pic. So now I expect it to fly! Been a good run recently, but their US operation will drain funds and Vs has no G'tees.
EDIT (2Nov10)- flying still, now 350 that's nearly 10% up on my Sale. Huh!

Edison now saying BTG worth 3.51 a share and mentions a very positive update on Campath, with a possible hostile bid by Sanofi-Aventiss for Genzyme, BTGs licensee for the drug, which contends its prospects are vastly under-appreciated.

Today Norges Bank informed the market that they had increased their holding from 7,689,369 to 9,189,369 and the sp drops. Strange world.

As yet I have not made my mind up re a good or bad move.
BGC shareholders obviously think that at the proposed price offer is a bad move, whereas holders of Biocompatibles have judged it a good move. With the offer being worth about 40% more than the price on the day Biocompatibles announced it had been approached you can see why. Biocompatibles are the obvious instant winners. Holders of BGC will have to wait and see, but to offer a premium of 40% look on the face of it, far too generous. Remembering back to the price BGC paid for Protherics shares, which were not in this league of premium paid, this proposed deal looks very generous indeed.
As said, not yet judging. Just waiting and watching.

I noticed the CEO sold over �200k=worth just earlier, and it's difficult to imagine there was zero inkling of the lead-up to Due Dilligence (don't these things take for ages?), still, BII was a hefty price and one that does one Co well can't be so good for the other. I saw the obvious connection with Protherics, Both "lost" and Gained.....=Evens.
Of course BII might have been less-keen with a lower price, but BGC needs that cash for Varisolve trials (and I still wonder why no-one else is a willing partner).
The SP is now below my Sale, only just. But why take any risk....I knew nothing of BII, incidently. . . my sale followed the IC article....quite the opposite of "Shares" this week!

I wonder if there will be a cash-call in the New Year? - or, will the City dilute existing shareholders with a Placing....?
EDIT -(15Dec10)- Seems I may be wrong, the BII deal is still subject to shareholder approval....still, we know what that means, don't we?
EDIT 30Jan2012)- Well a Day after the Management Report we have GOOD NEWS on Varisolve, but the effect on SP is not much.....

Still form 8.5s coming out showing short positions. Not good for the sp.

Edit.....Sorry wrong thread

BTG plc: Interim Management Statement

London, UK, 25 January 2012: BTG plc (LSE: BGC), the specialist healthcare company, today publishes its interim management statement for the period from 1 October 2011 to 24 January 2012.

Trading has been in line with the Board's expectations and revenues for the full year are expected to be in the range £160m to £165m, as previously announced. This guidance excludes any royalty revenues that may be received in the second half relating to BeneFIX® (factor IX) product that was in the supply chain at the time of final patent expiry in March 2011.

The Biologics License Application for Voraxaze® (glucarpidase) that was submitted to the US Food and Drug Administration in September 2011 was granted priority review and was approved on 17 January 2012. Voraxaze® is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per litre) in patients with delayed methotrexate clearance due to impaired renal function. It will be marketed directly in the US by BTG through our existing acute care sales force; we anticipate peak US sales of around $15m per annum. BTG licensed the Japanese rights to glucarpidase to Ohara Pharmaceutical Co., Ltd. in December 2011.

BTG's new team of Medical Science Liaisons and Account Managers commenced direct sales of and medical support for the LC Bead™ in the US this month following expiry of the distribution contract with AngioDynamics, Inc. on 31 December 2011. The team has made good initial progress, with all key accounts updated with new order codes and first orders received. The revenue impact of selling the LC Bead™ in the US ourselves is expected to be evident from the financial year beginning in April 2012.

Analysis of data from the Phase III trials of Varisolve® (PEM) is continuing with the results of all three studies expected within the first half of 2012.

Louise Makin, BTG's CEO, commented: "We have continued to make good progress commercially and in our pipeline since reporting in November a strong set of results for the first half of the year. Our second US sales force is now selling the LC Bead™ and has started well. We were pleased to receive US approval for Voraxaze®, the first regulatory application we have made in the US, which we will market through our existing acute care sales force. We look forward to a busy 2012, with data from the three Phase III trials of Varisolve®, from our partner AstraZeneca's Phase IIb study of AZD9773 (CytoFab™) in severe sepsis and the submission of US and EU regulatory applications by Sanofi for Lemtrada™ (alemtuzumab) in relapsing-remitting multiple sclerosis."